Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Posted on by sciencefather

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Mrs. Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Mrs. Marija Gjorgoska | Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana | Slovenia

Marija Gjorgoska is a dedicated biomedical researcher and teaching assistant at the Faculty of Medicine, University of Ljubljana, Slovenia. With a strong background in biochemistry, molecular biology, and bioinformatics, she has contributed significantly to cancer research, focusing on steroid hormone signaling in gynecological cancers. Her scientific work combines analytical expertise in LC-MS/MS with a solid foundation in molecular biology and statistical analysis using R programming. Marija is passionate about advancing clinical diagnostics and cancer treatment through high-precision biomolecular profiling. Her academic journey reflects international exposure through internships in the UK and Macedonia. She is known for her collaborative spirit and commitment to scientific rigor, which has led to multiple high-impact publications. Marija continues to mentor students and contribute to the academic community through her teaching role, making her a rising figure in molecular oncology research.

publication profile:

scopus

Strengths:

  1. High Research Productivity 📈
    Marija Gjorgoska has authored or co-authored 10 peer-reviewed publications in high-impact journals such as Progress in Lipid Research (IF 14.0), Trends in Endocrinology and Metabolism (IF 11.4), and Cancers. Her work shows consistent scientific output, often with first or shared first authorship.

  2. Cutting-Edge Technical Expertise 🔬
    She demonstrates advanced proficiency in LC-MS/MS method development, multi-steroid profiling, and bioinformatics (R programming). This makes her an expert in translational hormone research and biomarker discovery.

  3. Clinical Relevance and Innovation ⚕️
    Her research addresses urgent clinical challenges like endometrial cancer diagnosis and ovarian cancer drug resistance, applying modern analytical techniques combined with machine learning, which positions her at the forefront of personalized medicine.

  4. Recognition and Collaboration 🤝
    She has been awarded prestigious grants (e.g., Society of Endocrinology, UK), collaborated internationally (UK, Macedonia), and contributes to academia as a teaching assistant—all signs of an emerging research leader.

  5. Interdisciplinary Impact 🌐
    Marija effectively integrates molecular biology, biochemistry, analytical chemistry, and computational biology—indicative of her versatility and broad scientific impact.

Areas for Improvement:

  1. Independent Research Leadership
    While she has made substantial contributions as a junior and co-investigator, future work could benefit from establishing herself as a principal investigator or project leader, including securing her own research funding.

  2. Diversification of Research Themes
    Her focus has been predominantly on hormone-related cancers. Expanding into other disease models or mechanisms could broaden her impact and create new collaborative opportunities.

  3. Public Engagement and Outreach
    Enhancing her visibility through conference presentations, science communication, or community health initiatives would further solidify her standing as a leader and advocate for biomedical research.

Education :

Marija Gjorgoska is currently enrolled in a doctoral program in Biomedicine, specializing in Biochemistry and Molecular Biology at the University of Ljubljana. Her academic foundation includes a Master’s degree in Molecular Biology (2018–2021) from the same university, completed with an outstanding GPA of 9.52/10. She also gained international experience through a short-term internship at the University of Birmingham, UK, in 2023, focusing on advanced LC-MS/MS techniques for clinical sample analysis. Earlier in her academic career, she completed a long-term internship at the Research Center for Genetic Engineering and Biotechnology in Skopje, Macedonia (2017), where she worked on genetic diagnostics involving haemoglobinopathies, HPV, HBV, and HCV detection. Her education has consistently emphasized both theoretical knowledge and hands-on laboratory skills, particularly in analytical chemistry, molecular biology, and bioinformatics, all of which shape her current research endeavors in cancer diagnostics and hormonal regulation.

Experience:

Marija Gjorgoska has been actively engaged in research since 2020 as a Research Assistant at the Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana. Her core responsibilities include developing and validating LC-MS/MS analytical methods, conducting proteomic and genetic analyses of cancer tissues, and performing bioinformatic evaluations using R programming. In October 2024, she also began serving as a Teaching Assistant for the course “Principles of Biochemistry,” demonstrating her commitment to education and mentorship. Marija’s prior internships have equipped her with valuable skills in prenatal and infectious disease diagnostics. Her research contributions span experimental planning, scientific writing, and instrument maintenance, establishing her as a versatile scientist. Her collaborative projects with international researchers and clinicians further underline her strength in translational biomedical research. This combination of teaching, laboratory, and analytical expertise supports her growing influence in molecular oncology.

Awards and Honors:

Marija Gjorgoska has been recognized for both academic and research excellence. In 2023, she was awarded the Practical Skills Grant by the Society of Endocrinology, UK, enabling her to undergo advanced training in LC-MS/MS at the University of Birmingham. Earlier, in 2021, she received the Krka Recognition with Special Praise for her Master’s thesis, highlighting her early promise as a researcher in molecular biology. Her scientific publications have appeared in top-tier journals such as Progress in Lipid Research and Trends in Endocrinology and Metabolism, some with impact factors exceeding 14.0. Notably, she earned shared first co-authorship in Methods in Enzymology for her work on enzymatic assay development. These accolades reflect her technical excellence, originality, and scientific contributions in the field of steroid metabolism and gynecological cancers. Marija’s achievements distinguish her as a young researcher with significant impact and high potential for further contributions to science and medicine.

Research Focus :

Marija Gjorgoska’s research focuses on the role of steroid hormones in the development and progression of gynecological cancers, particularly endometrial and ovarian cancers. Her work integrates analytical chemistry (LC-MS/MS), bioinformatics, and molecular biology to uncover diagnostic and prognostic biomarkers. She has developed multi-steroid profiling techniques to differentiate between normal and cancerous tissues, aiding early diagnosis. Marija’s studies also address the pre-receptor regulation of androgenic and estrogenic hormones, exploring their signaling dynamics at the tissue level. Using tools such as Mendelian randomization, she investigates genetic influences on hormone-related disease risk. Her interdisciplinary approach combines advanced mass spectrometry, statistical modeling, and clinical collaboration to translate bench science into meaningful medical applications. Through high-impact publications, she contributes to understanding hormone metabolism in cancer microenvironments, with the goal of informing targeted therapies and overcoming drug resistance. Her work is critical for advancing personalized medicine in hormone-driven malignancies.

Publications Top Notes:

  1. 📘 From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling – Progress in Lipid Research, 2024

  2. 📘 Integration of androgen hormones in endometrial cancer biology – Trends in Endocrinology and Metabolism, 2022

  3. 📘 Steroid sulfatase and sulfotransferases in gynecological cancers: current status and perspectives – Essays in Biochemistry, 2024

  4. 📘 Estrogens and the Schrödinger’s cat in the ovarian tumor microenvironment – Cancers, 2021

  5. 📘 Multi-Steroid Profiling and Machine Learning Reveal Androgens as Biomarkers for Endometrial Cancer – Cancers, 2025

  6. 📘 Simultaneous measurement of 17 endogenous steroid hormones by LC-MS/MS – J. of Steroid Biochemistry and Molecular Biology, 2024

  7. 📘 11-oxyandrogens in normal vs. cancerous endometrium – Frontiers in Endocrinology, 2024

  8. 📘 Targeting estrogen metabolism to overcome platinum resistance in ovarian cancer – Biomedicine & Pharmacotherapy, 2024

  9. 📘 Effect of androgens on risk of endometriosis sub-phenotypes and ovarian neoplasms – J. of Steroid Biochemistry and Molecular Biology, 2024

  10. 📘 Enzymatic assays for 17β-HSD types 1 and 2 using mass spectrometry – Methods in Enzymology, 2023

Conclusion:

Marija Gjorgoska is a highly promising early-career researcher with a strong and growing international publication record, deep technical expertise in analytical biochemistry, and a clear focus on clinically relevant research. Her integration of hormonal pathway analysis with state-of-the-art analytical methods has already contributed valuable insights to the field of gynecological oncology. She has the academic rigor, curiosity, and collaborative drive essential for impactful science.

In my opinion, she is a highly suitable candidate for the Best Researcher Award. Continued mentorship and support toward independent research leadership will elevate her even further in the years to come.

Tao Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Tao Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Tao Zhang, South China Normal University, China

Dr. Tao Zhang is a distinguished Professor at the College of Biophotonics, South China Normal University, where he has been advancing the frontiers of chemical biology and phototheranostics. With a keen focus on developing innovative optical probes and imaging techniques for tumor diagnosis and treatment, Dr. Zhang has made significant contributions to the field of lanthanide chemistry and biomedical imaging. His academic journey spans from Ningbo University (MPhil) to earning his Ph.D. in Chemistry from Hong Kong Baptist University. As a corresponding author on numerous high-impact publications and a recipient of multiple prestigious provincial awards, Dr. Zhang has earned recognition for both research excellence and academic leadership. He is actively involved in interdisciplinary collaborations, producing over 40 peer-reviewed publications in journals such as Nature Communications, PNAS, JACS, and Advanced Science. His ongoing work addresses critical challenges in imaging-guided therapies for cancer under hypoxic and complex microenvironment conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📈 Outstanding Research Output
    Dr. Zhang has published over 40 peer-reviewed articles in top-tier journals such as Nature Communications, Advanced Science, JACS, ACS Nano, and PNAS. These works cover cutting-edge topics in photodynamic therapy, tumor imaging, and nanotechnology—key areas in modern biomedical research.

  2. 🧪 Innovation in Biomedical Chemistry
    He has demonstrated consistent originality by designing oxygen-independent Type I pro-photosensitizers, reversible ratiometric photoacoustic probes, and multimodal imaging nanoplatforms, all of which target real-world challenges in hypoxic tumor environments.

  3. 🌏 National Recognition
    His research excellence has been recognized by prestigious awards such as the Special Support Program for Young Top-notch Talents of Guangdong Province and the Pearl River Science and Technology Rising Star of Guangzhou, both in 2018.

  4. 🎯 Multidisciplinary Expertise
    With a strong background in lanthanide chemistry, chemical biology, and optical imaging, Dr. Zhang successfully bridges multiple fields, demonstrating a holistic approach to solving biomedical challenges.

  5. 📚 Leadership Role
    As a corresponding author on many publications, he plays a leading role in both research direction and execution. His progression from Assistant to Full Professor between 2014 and 2021 further reflects his capability as a research leader.

🛠️ Areas for Improvement:

  1. 🌐 International Collaborations & Visibility
    While Dr. Zhang has co-authored with international researchers, expanding his global collaborative network through joint grants, keynote talks, or leadership in international consortia could further enhance his profile.

  2. 👨‍🏫 Public Outreach & Technology Transfer
    Increasing efforts in public science communication, patenting innovations, or transitioning lab technologies into clinical trials could strengthen his case for broader societal impact.

  3. 📢 Social & Digital Engagement
    A higher digital or social media presence (e.g., ResearchGate, Google Scholar metrics, professional website updates) would make his research more visible to the global community and potential collaborators.

🎓 Education:

Dr. Tao Zhang embarked on his academic career with an MPhil in Inorganic Chemistry from Ningbo University (2006–2009), where he conducted research under Professor Hongze Liang. He furthered his education by pursuing a Ph.D. in Chemistry at Hong Kong Baptist University (2009–2013), mentored by Professors Wai-Kwok Wong and Ka-Leung Wong. His doctoral research focused on lanthanide coordination chemistry and bioimaging, setting a strong foundation for his future innovations in photodynamic therapy and tumor diagnostics. These formative years not only shaped his technical expertise in spectroscopy and nanomaterials but also cultivated a rigorous research ethic that has carried through his academic trajectory. His education was marked by cross-disciplinary training in synthetic chemistry, photophysics, and biological applications, providing him with a broad and robust skill set that continues to support his ongoing exploration in chemical biology and optical probes for clinical imaging and therapeutic interventions.

💼 Experience:

Dr. Zhang’s academic career at South China Normal University’s College of Biophotonics began in 2014 as an Assistant Professor. He was promoted to Associate Professor in 2017 and then to full Professor in 2021. Throughout his academic appointments, Dr. Zhang has led innovative research in tumor imaging, photothermal therapy, and optical diagnostics, establishing a productive research group known for creative nanoprobe design and translational research. His lab has secured multiple research grants and frequently collaborates with international researchers, combining chemical innovation with biomedical applications. Dr. Zhang has mentored graduate students and postdocs, many of whom have gone on to prestigious research positions. His steady academic progression reflects both his research productivity and leadership in the field of phototheranostics. Over the years, his expertise has positioned him at the forefront of integrating nanotechnology and chemistry into next-generation diagnostic and therapeutic platforms for treating cancer and understanding tumor microenvironments.

🏆 Awards and Honors:

Dr. Tao Zhang has received multiple prestigious awards that underscore his exceptional research contributions and scientific leadership. In 2018, he was honored with the Special Support Program for Young Top-notch Talents of Guangdong Province, recognizing his pioneering work in optical molecular probes for cancer imaging. That same year, he also received the Pearl River Science and Technology Rising Star of Guangzhou, further validating the impact and innovation of his interdisciplinary research in chemical biology. These accolades highlight his rising prominence as a researcher capable of translating basic chemical discoveries into practical medical technologies. He is consistently invited to contribute as a corresponding author in top-tier journals, reflecting the high regard his peers have for his scientific insight and rigor. These honors not only reflect personal achievement but also enhance the prestige of the College of Biophotonics at South China Normal University, where he continues to lead cutting-edge research.

🔍 Research Focus:

Dr. Tao Zhang’s research focuses on the convergence of Chemical Biology, Lanthanide Chemistry, and Optical Imaging Technologies for cancer diagnosis and treatment. His main interest lies in developing smart, light-activated nanomaterials and photosensitizers that enable precise imaging and phototherapy, particularly in hypoxic tumor microenvironments. His team is advancing Type I photodynamic therapy agents and oxygen-independent systems, addressing critical limitations in current cancer treatment modalities. Another core area of his research is the creation of upconversion nanoparticles and ratiometric probes for real-time, non-invasive imaging—capable of dual-modality functionality (fluorescence and photoacoustic). Leveraging lanthanide chemistry, Dr. Zhang also contributes to MRI contrast agent innovation and multimodal diagnostics. His cross-disciplinary work integrates synthetic chemistry, molecular design, and biological application, offering new avenues for theranostics. His cutting-edge research is published in leading journals, pushing the boundaries of tumor imaging, molecular sensing, and personalized cancer therapy with minimal invasiveness and enhanced specificity.

📚 Publications Top Notes:

  1. 🧬 Totally Caged Type I Pro-Photosensitizer for Oxygen-Independent Synergistic Phototherapy of Hypoxic Tumors – Advanced Science, 2024

  2. 🔁 Switching the NIR Upconversion of Nanoparticles for Orthogonal Activation of Photoacoustic Imaging and Phototherapy – Nature Communications, 2022

  3. 🧪 Dynamic-Reversible Photoacoustic Probe for Continuous Ratiometric Sensing and Imaging of Redox Status In Vivo – JACS, 2019

  4. 🎯 In Vivo Imaging-Guided Photothermal/Photoacoustic Synergistic Therapy with Tumor-Targeting Nanoparticles – ACS Nano, 2017

  5. 💥 In Vivo Selective Cancer-Tracking Gadolinium Eradicator as New-Generation Photodynamic Therapy Agent – PNAS, 2014

  6. 🧫 ROS-Catalytic Self-Amplifying Benzothiophenazine-Based Photosensitive Conjugates for Photodynamic-Immuno Therapy – Biomaterials, 2025

  7. 🧬 A Self-Catalytic UCNP-Based Nanomachine for Highly Sensitive Detection of CTCs – Biosensors and Bioelectronics, 2025

  8. 🔍 An AND-Gate Photoacoustic Probe for Cys and H2S Precise Photoacoustic Sensing in Tumors – Anal. Chem., 2024

  9. 🎨 Single Side-Chain-Modulatory of Hemicyanine for Fluorescence and Photoacoustic Dual-Modality Imaging – Small Methods, 2024

  10. 🌫️ High-Contrast Photoacoustic Imaging of Localized Cysteine in Breast Cancer – Chem. Eur. J., 2024

🧾 Conclusion:

Dr. Tao Zhang is highly suitable for the Best Researcher Award due to his exceptional scholarly output, innovative biomedical applications, and proven academic leadership. His work addresses some of the most critical challenges in cancer diagnostics and therapy using chemical tools and photonic technology.

baofeng wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. baofeng wang | Cancer Cell Biology | Best Researcher Award

Prof. baofeng wang, Department of Radiation Therapy, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an 710004, China, China

Dr. Baofeng Wang is a Professor and Associate Chief Physician at The Second Affiliated Hospital of Xi’an Jiaotong University. He serves as Head of the Abdominal Oncology Group in the Department of Radiation Oncology and is a Master’s Supervisor. Renowned for his expertise in abdominal and liver cancers, Dr. Wang actively contributes to several professional organizations, including the Chinese Society for Radiation Oncology (CSRO). As a reviewer for top journals and a recipient of multiple prestigious research awards, his work integrates clinical excellence with cutting-edge research. He has led three national and provincial-level projects and has authored over 40 scientific articles, with more than 10 published in SCI-indexed journals. His recent work focuses on ferroptosis, immune regulation in cancer, and BNCT treatment planning, marking him as a leading figure in translational oncology research.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Academic and Clinical Leadership:

    • Professor, Associate Chief Physician, and Master’s Supervisor.

    • Head of the Abdominal Oncology Group at a leading national medical institution.

    • Actively leads and shapes treatment protocols in radiation oncology.

  2. Research Productivity and Impact:

    • Authored over 40 scientific publications, with more than 10 indexed in SCI journals.

    • Principal Investigator for 3 major funded research projects.

    • Co-investigator in 5 additional national and provincial projects.

    • Reviewer for high-impact international journals, ensuring scientific rigor in oncology research.

  3. Recognition and Awards:

    • Winner of two First Prizes for Scientific and Technological Progress in Higher Education Institutions.

    • Received a Second Prize from the Shaanxi Provincial Scientific and Technological Progress Awards.

  4. Professional Influence:

    • Holds multiple key positions in national and provincial medical societies, especially within the Chinese Society for Radiation Oncology (CSRO).

    • Active in bridging research, clinical practice, and public health education.

  5. Recent Research Focus:

    • Investigating mechanisms of radioresistance via ferroptosis and cholesterol metabolism.

    • Advancing boron neutron capture therapy (BNCT) planning and immunoregulatory pathways in breast cancer and hepatocellular carcinoma.

⚙️ Areas for Improvement:

  1. Global Collaboration:

    • While domestically influential, expanding international collaborations and partnerships could further elevate the research impact and visibility.

  2. Citation Index and Research Translation:

    • Despite a good number of publications, a higher citation count and more translational outcomes into clinical practice would strengthen the award candidacy further.

  3. Innovation Leadership:

    • Developing patents or pioneering novel therapeutic technologies would add to innovation metrics.

🎓 Education:

Dr. Baofeng Wang received rigorous academic training in the medical sciences, specializing in oncology and radiation therapy. After completing his undergraduate medical degree, he pursued postgraduate studies focused on radiation oncology and tumor biology. His advanced academic pursuits led to a comprehensive understanding of radiobiology, imaging-guided radiotherapy, and molecular oncology. He continuously updates his knowledge through professional development programs and has contributed to both educational and research domains by mentoring postgraduate students. His commitment to academic excellence is evident through his role as a Master’s Supervisor, guiding the next generation of clinical researchers. Dr. Wang’s educational background has equipped him with the skills necessary to integrate evidence-based medicine with innovative research, particularly in the fields of liver cancer and immuno-oncology.

🧪 Professional Experience:

With over 15 years of clinical and academic experience, Dr. Baofeng Wang is a leading figure in the field of radiation oncology. Currently a Professor and Associate Chief Physician, he heads the Abdominal Oncology Group at The Second Affiliated Hospital of Xi’an Jiaotong University. He has been instrumental in developing individualized radiotherapy protocols for complex tumors. His leadership roles in various national and provincial oncology organizations highlight his influence in shaping cancer treatment strategies. He has served as Principal Investigator for several research grants from the National Natural Science Foundation of China and provincial R&D bodies. Additionally, Dr. Wang plays an active role in academic peer review and science promotion in Shaanxi province. His blend of clinical acumen and research proficiency makes him a cornerstone in the advancement of radiotherapy techniques and translational oncology.

🔬 Research Focus:

Dr. Wang’s research focuses on the intersection of radiation oncology, tumor metabolism, and immunoregulation. He investigates how cellular mechanisms such as ferroptosis and cytokine modulation contribute to radioresistance and tumor progression. A major area of interest is the optimization of boron neutron capture therapy (BNCT) treatment planning, aiming to enhance therapeutic outcomes in abdominal cancers. His work also explores the role of tumor-infiltrating immune cells and how factors like interleukin-10 influence immune suppression and therapy response. By integrating molecular diagnostics with imaging-guided radiotherapy, Dr. Wang seeks to improve precision medicine strategies. His translational research aims to convert lab-based discoveries into clinically viable cancer treatments, particularly for liver, breast, and gastrointestinal cancers. Through collaborative and interdisciplinary research, Dr. Wang’s work continues to push boundaries in oncology innovation.

📚 Publications Top Notes:

  1. 🧬 Recent research progress of BNCT treatment planning system

  2. 🔗 SCARB1 links cholesterol metabolism-mediated ferroptosis inhibition to radioresistance in tumor cells

  3. 🎯 BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

  4. 🛡️ Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

📌 Conclusion:

Dr. Baofeng Wang exemplifies the qualities of an exceptional clinical researcher, balancing leadership, clinical service, and impactful research. His contributions to radiation oncology—particularly in abdominal and liver cancers—along with national-level recognition and funding, make him a highly suitable and competitive candidate for the Best Researcher Award. Continued expansion of his international footprint and translational outputs would position him even more prominently on the global stage.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

  1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

  2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

  3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

  4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

  5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

  6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.